

U.S. Appl. No. 09/476,485
Our Ref. No.: PHY-003US1/108236.119
Comm. Resp. to Examiner Inquiry dated November 22, 2004

EXHIBIT A

Listing of Pending Claims:

Claims 1-73. (Canceled)

Claim 74. (Previously Presented): A pharmaceutical formulation comprising:

(a) a pharmaceutically acceptable carrier; and

(b) a protein that:

(1) binds to a normally glycosylated FLT3 receptor;

(2) has at least 95% amino acid sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, and SEQ ID NO: 8; and

(3) preserves hematopoietic progenitor cells.

Claim 75. (Canceled)

Claim 76. (Previously Presented): The pharmaceutical formulation of claim 84, wherein said subject is a human undergoing treatment for cancer.

Claim 77. (Previously Presented): The pharmaceutical formulation of claim 84, wherein said therapeutic treatment is selected from the group consisting of radiotherapy, chemotherapy, or a combination of radiotherapy and chemotherapy.

Claim 78. (Previously Presented): The pharmaceutical formulation of claim 77, wherein said chemotherapy comprises administration of a chemotherapeutic selected from the group consisting of cytarabine, doxorubicin, and 5-fluorouracil.

Claim 79. (Previously Presented): The pharmaceutical formulation of claim 74 or 84, wherein said pharmaceutical formulation is suitable for parenteral administration.

U.S. Appl. No. 09/476,485

Our Ref. No.: PHY-003US1/108236.119

Comm. Resp. to Examiner Inquiry dated November 22, 2004

Claim 80. (Previously Presented): The pharmaceutical formulation of claim 79, wherein said parenteral administration is selected from the group consisting of intravenous, intra-arterial, subcutaneous, intramuscular, intraperitoneal and intra-marrow administration.

Claim 81. (Previously Presented): The pharmaceutical formulation of claim 74 or 84, wherein said protein comprises the amino acid sequence of SEQ ID NO: 2.

Claim 82. (Previously Presented): The pharmaceutical formulation of claim 74 or 84, wherein said protein comprises the amino acid sequence of SEQ ID NO: 6.

Claim 83. (Previously Presented): The pharmaceutical formulation of claim 74 or 84, wherein said protein comprises the amino acid sequence of SEQ ID NO: 8.

Claim 84. (Previously Presented): A pharmaceutical formulation comprising:

(a) a pharmaceutically acceptable carrier; and

(b) an effective amount of a protein that:

(1) binds to a normally glycosylated FLT3 receptor;

(2) has at least 95% amino acid sequence identity to an amino acid sequence

selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, and SEQ ID NO: 8;

and

(3) reduces a progenitor cell depleting activity in a subject undergoing a therapeutic treatment having progenitor cell depleting activity.